Teleflex (TFX) Q2 2025 Earnings Call July 31, 2025 08:00 AM ET Company ParticipantsLawrence Keusch - VP - IR & Strategy DevelopmentLiam Kelly - Chairman, President & CEOJohn Deren - EVP & CFOMatt Taylor - Managing DirectorJayson Bedford - MD - Medical TechnologyAnthony Petrone - MD - Equity ResearchRichard Newitter - Managing DirectorConference Call ParticipantsShagun Singh - Medical Technology AnalystNone - AnalystMike Polark - Senior Equity Research Analyst - Medical DevicesMike Matson - MD - Senior Equit ...

Teleflex (TFX) Q2 2025 Earnings Call July 31, 2025 08:00 AM ET Speaker0morning, ladies and gentlemen, and welcome to the Teleflex Second Quarter twenty twenty five Earnings Conference Call. At this time, all participants have been placed in a listen only mode. At the end of the company's prepared remarks, we will conduct a question and answer session. Please note that this conference call is being recorded and will be available on the company's website for replay shortly. And now, I will turn the call over ...

Teleflex (TFX) came out with quarterly earnings of $3.73 per share, beating the Zacks Consensus Estimate of $3.36 per share. This compares to earnings of $3.42 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +11.01%. A quarter ago, it was expected that this medical equipment maker would post earnings of $2.88 per share when it actually produced earnings of $2.91, delivering a surprise of +1.04%.Over the last four quarters, the ...

Second Quarter 2025 Earnings Conference Call 7/31/2025 Teleflex Incorporated Conference Call Logistics The release, accompanying slides, and replay webcast are available online at www.teleflex.com (click on Investors) An audio replay of the call will be available beginning at 11:00 am Eastern Time on July 31, 2025 either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S.) or 1 609 800 9909 (all other locations). The confirmation code is 69028. Today's Speakers ...

Exhibit 99.1 FOR IMMEDIATE RELEASE July 31, 2025 Teleflex Reports Second Quarter Financial Results and Full Year 2025 Outlook Wayne, PA -- Teleflex Incorporated (NYSE: TFX) (the "Company") today announced financial results for the second quarter ended June 29, 2025. • Raising GAAP revenue growth guidance range to 9.00% to 10.00% • Raising adjusted constant currency revenue growth guidance range to 7.70% to 8.70% • Raising GAAP EPS from continuing operations guidance range to $6.73 to $7.13 • Raising adjuste ...

Core Insights - Teleflex Incorporated reported solid second quarter results with an increase in constant currency revenue growth and adjusted earnings per share compared to the prior year [3][6] - The company successfully completed the acquisition of BIOTRONIK's Vascular Intervention business, which positively impacted the 2025 adjusted constant currency revenue guidance [3][9] - The company is focused on unlocking value through the separation of NewCo and exploring options to maximize shareholder value [3] Financial Performance - For the three months ended June 29, 2025, consolidated net revenue was $780.9 million, reflecting a 4.2% increase compared to $749.7 million in the prior year [5][6] - Adjusted diluted earnings per share from continuing operations for the second quarter was $3.73, up from $3.42 in the prior year [6][10] - The company raised its full year 2025 GAAP revenue growth guidance to a range of 9.00% to 10.00% and adjusted constant currency revenue growth guidance to 7.70% to 8.70% [9][10] Revenue by Segment - In the Americas, net revenue for the three months ended June 29, 2025, was $525.7 million, a 1.9% increase from $515.6 million in the prior year [5] - EMEA segment revenue increased by 13.0% to $166.2 million, while Asia segment revenue grew by 2.3% to $89.0 million [5] - For the six months ended June 29, 2025, consolidated net revenue was $1,481.6 million, a slight decrease of 0.4% compared to $1,487.5 million in the prior year [5][6] Product Category Performance - The Interventional product category saw significant growth, with revenue increasing by 20.4% to $170.0 million for the three months ended June 29, 2025 [8] - Vascular Access revenue grew by 2.4% to $185.5 million, while Anesthesia and OEM categories experienced declines of 6.0% and 11.4%, respectively [8] - For the six months ended June 29, 2025, Interventional revenue increased by 11.5% to $307.6 million, while Anesthesia and OEM categories saw declines of 8.0% and 19.2%, respectively [8][36] Outlook - The company expects the acquisition of the Vascular Intervention business to generate approximately $204 million in revenue in the second half of 2025 [9] - The adjusted diluted earnings per share guidance for 2025 was raised to a range of $13.90 to $14.30, reflecting a year-over-year increase [10][14] - The company anticipates a positive impact of approximately 0.85% from foreign exchange rate fluctuations for the full year [9][11]

Core Insights - The chest drainage catheters market is projected to grow at a CAGR of 4.78% from 2025 to 2032, driven by the increasing prevalence of chronic conditions such as cancer and cardiovascular diseases, along with advancements in catheter technology and improved healthcare access [2][6]. Market Dynamics - In 2022, there were 2,480,675 reported cases of lung-related cancers, predominantly in Asia, which significantly boosts the demand for thoracic drainage interventions using chest drainage catheters [3]. - Approximately 620 million people globally are living with heart and circulatory diseases, further driving the need for interventions like pericardial effusions management through chest drainage catheters [4]. Technological Advancements - The adoption of minimally invasive procedures is enhancing the chest drainage catheter market by improving procedural precision and patient outcomes, with innovations such as image-guided catheter placements and smart catheters enabling real-time monitoring [5]. Challenges - The market faces challenges including catheter complexity and stringent regulatory requirements, which may limit growth; however, the demand for safe and effective thoracic drainage solutions continues to rise due to the increasing global burden of cancer and cardiovascular diseases [6]. Segment Analysis - Pleural drainage catheters are expected to lead the market in 2024, driven by the rise in pleural diseases associated with lung cancer and heart failure, with features like tunneled indwelling pleural catheters offering less invasive alternatives [7]. Manufacturer Innovations - Manufacturers are advancing catheter designs by incorporating features such as smaller diameters, anti-microbial coatings, and integration with digital drainage systems, enhancing safety and clinical outcomes [8]. Regional Outlook - North America is anticipated to dominate the chest drainage catheters market in 2024, supported by an increasing number of cancer patients, advanced healthcare infrastructure, and the presence of key market players like BD, Teleflex Incorporated, and Cook [9][10]. Key Players - Leading companies in the chest drainage catheters market include BD, Teleflex Incorporated, Cook, ICU Medical, and Redax S.p.A., among others [10][12]. Recent Developments - In June 2021, BD received FDA 510(k) clearance for its PeritXT Peritoneal Catheter System, intended for symptomatic, non-malignant ascites drainage [11]. Conclusion - The chest drainage catheters market is poised for substantial growth from 2025 to 2032, with North America being a significant contributor to this expansion [11].

Core Points - Teleflex Incorporated will host a conference call to discuss its second quarter financial results and provide an operational update on July 31, 2025 at 8:00 a.m. Eastern Time [1] - An audio replay of the call will be available starting at 11:00 a.m. Eastern Time on the same day [2] - Teleflex is a global provider of medical technologies focused on improving health and quality of life, with a diverse portfolio in various therapy areas [3] - The company is known for its trusted brands such as Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™ Rüsch™, UroLift™, and Weck™ [4]

Company Overview - Teleflex has completed the acquisition of the majority of BIOTRONIK SE & Co. KG's Vascular Intervention business for €760 million, significantly enhancing its interventional access product line and global presence in cath labs [1][8] - The acquired business includes a diverse portfolio of coronary and peripheral intervention products, which are expected to bolster Teleflex's innovation pipeline [4][5] Financial Impact - The acquisition is projected to add $0.10 to Teleflex's adjusted earnings per share (EPS) in the first year, with increasing contributions in subsequent years [10] - Teleflex anticipates that the acquired products will generate revenues of €177 million ($204 million) in the second half of 2025, with a constant currency revenue growth expectation of 6% or better from 2026 onward [9] Market Context - The vascular intervention medical devices market was valued at $5.1 billion in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 7.1% through 2033, driven by the rising prevalence of cardiovascular diseases and advancements in technology [11] Recent Developments - Teleflex has announced findings from a multinational study demonstrating the effectiveness of Arrow Chlorhexidine-Impregnated Central Venous Catheters, showing a 70.5% reduction in the incidence of CLABSI [12]

Core Viewpoint - Teleflex has completed the acquisition of Biotronik's Vascular Intervention business for nearly $900 million, enhancing its product portfolio in the interventional treatment market and positioning itself as a stronger competitor in the growing peripheral intervention market [1][15][20] Summary by Sections Acquisition Details - Teleflex announced the early completion of its acquisition of Biotronik's Vascular Intervention business, with a total transaction price of nearly $900 million (approximately 6.4 billion RMB) [1] - The acquisition integrates Biotronik's core assets in coronary and peripheral vascular intervention into Teleflex's product lineup [1] Biotronik VI Products and Technologies - The acquisition includes several high-tech interventional treatment products such as: - **Orsiro Drug-Eluting Stent (DES)**: A biodegradable polymer-coated stent designed to reduce long-term inflammation risks and improve vascular compliance [3] - **Pantera Lux Drug-Coated Balloon (DCB)**: A non-implant treatment option that releases drugs to inhibit vascular smooth muscle proliferation [6] - **PK Papyrus Covered Stent**: The first FDA-approved stent for acute coronary perforation, designed for flexibility and delivery performance [9] - **Freesolve Absorbable Magnesium Stent (RMS)**: A stent that fully degrades within 12 months, providing temporary mechanical support without long-term metal presence [12] Strategic Rationale for Teleflex - Teleflex aims to transition from a focus on access products to therapeutic devices, enhancing its market position and profitability [14] - The acquisition allows Teleflex to enter the high-value treatment market, with products that have significant technological barriers [14] - The global peripheral intervention market is projected to exceed $10 billion by 2030, with a compound annual growth rate of 7.3%, highlighting the strategic importance of this acquisition [15] Biotronik's Strategic Shift - Biotronik's decision to divest its Vascular Intervention business aligns with its strategy to concentrate resources on high-growth areas such as cardiac devices and digital health [16][17] - The divestiture reflects Biotronik's recognition of the competitive and capital-intensive nature of the vascular intervention market [17] Market Dynamics - The acquisition positions Teleflex in a competitive landscape dominated by major players like Boston Scientific and Medtronic, with products like Orsiro showing competitive advantages in clinical studies [18] - Teleflex's entry into the peripheral intervention market, previously dominated by larger companies, could disrupt existing market dynamics [19] - The future of Freesolve remains uncertain, but if it demonstrates safety and efficacy in clinical trials, it could revitalize the absorbable stent market [19] Conclusion - The acquisition signifies a strategic upgrade for Teleflex, transitioning from a supplier of access devices to a competitor in therapeutic interventional products [20] - Biotronik's divestiture allows it to focus on active implantable devices and digital health, paving the way for future growth [20]